The Column Group
Venture capitalActively deployingSan Francisco Β· Pre-SeedβLate Stage
Investment thesis
The Column Group pursues a dual-focused venture capital strategy centered on advancing science through biotech and technology ventures. The firm employs an edge-to-edge investment model that combines company formation capabilities with sustained capital deployment across private and public markets, leveraging an ecosystem of specialized funds to maximize success through collaborative action and support ventures from inception through exit.
Source: firm website, verified Jul 21, 2026.
What they invest in
from 11 of 43 portfolio companiesBiotech Γ10Medical Devices Γ8Healthtech Γ4AI & Machine Learning Γ3Deep Tech Γ3Digital Health Γ2Cybersecurity Γ1Developer Tools Γ1
HQs:United StatesΓ7
Investments Β· 43 tracked
founders shown can be your intro pathRemix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders. The company applies precision medicine approaches across oncology and other therapeutic areas.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)
Tau provides formal verification of compiled binaries by generating mathematical proofs of correctness or identifying bugs, addressing risks from AI-assisted code generation and complex software systems.
AI & Machine LearningCybersecurityDeveloper ToolsEnterprise SoftwareSan Francisco, US
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies. The company serves cancer patients and their caregivers globally.
BiotechDigital HealthHealthtechMedical Devices
David J. Earp(President & CEO)Matthew P. Jacobson(Co-founder)
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas. The company focuses on creating transformative treatments for patients in high-need therapeutic categories.
BiotechHealthtechMedical DevicesNew York, US
Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.
BiotechHealthtechMedical DevicesRahway, US
InduPro develops proximity-based therapeutics that manipulate spatial relationships of cell surface proteins to enable new disease treatments. The company specializes in protein proximity design for pharmaceutical applications.
BiotechDeep TechMedical DevicesSeattle, US
Kallyope discovers and develops novel therapeutics targeting previously unexplored neural networks, with lead programs in acute migraine treatment and novel metabolism disorders. The company leverages its proprietary Klarity platform to identify differentiated drug candidates for patients with challenging diseases.
BiotechDeep TechMedical DevicesNew York City, US
NGM Bio develops NGM120, a monoclonal antibody targeting the GDF15/GFRAL pathway, to treat hyperemesis gravidarum and cancer cachexia. The company is running Phase 2 clinical trials for both indications.
BiotechFemTechMedical Devices
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2Ξ± for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep Tech
Michael Martin, Ph.D.(Chief Executive Officer, President)Mike Grey(Executive Chairman)Jorge F. DiMartinoMichael Martin(President, Chief Executive Officer)
Johnson & Johnson is a diversified healthcare company operating across 260 subsidiary companies with approximately 138,000 employees globally. The organization develops pharmaceuticals, medical devices, and healthcare solutions across therapeutic areas including cardiology, oncology, immunology, neuroscience, and orthopaedics, alongside digital health and surgical robotics technologies.
BiotechHealthtechMedical DevicesNew Brunswick, US
Frequently asked questions
- What stage does The Column Group invest at?
- The Column Group invests at the Pre-Seed, Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does The Column Group focus on?
- The Column Group focuses on Biotech, Deep Tech.
- Where is The Column Group located?
- The Column Group is headquartered in San Francisco, US.
Images
Similar investors
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
Octopus Ventures is a pan-European early-stage venture capital firm that invests from pre-seed through Series A and beyond, with pre-seed investments typically at Β£100k and later-stage investments starting at Β£1 million.
F Prime Capital is an investment firm composed of scientists, engineers, physicians, operators, and investors who provide real-world expertise to help portfolio companies accelerate their path to scalable growth.
Vida Ventures is a life sciences investment firm founded by scientists, physicians, entrepreneurs and investors focused on advancing transformative biomedical innovations. The firm operates with a flexible, stage-agnostic approach across therapeutic areas.
Apple Tree Partners is a life sciences venture capital firm that creates and builds transformative biotechnology companies from early-stage science through public markets. The firm works with scientists at various stages, from pre-IP ideas to company spinouts, providing capital, strategic guidance, and operational resources.